Diagnostic and prognostic role of pancreatic secretory granule membrane major glycoprotein 2 (GP2) immunohistochemistry: A TMA study on 27,681 tumors
Standard
Diagnostic and prognostic role of pancreatic secretory granule membrane major glycoprotein 2 (GP2) immunohistochemistry: A TMA study on 27,681 tumors. / Uhlig, Ria; Günther, Karin; Bröker, Nina; Gorbokon, Natalia; Lennartz, Maximilian; Dwertmann Rico, Sebastian; Reiswich, Viktor; Viehweger, Florian; Büscheck, Franziska; Kluth, Martina; Hube-Magg, Claudia; Hinsch, Andrea; Fraune, Christoph; Bernreuther, Christian; Lebok, Patrick; Sauter, Guido; Izbicki, Jakob R; Steurer, Stefan; Burandt, Eike; Marx, Andreas H; Krech, Till; Simon, Ronald; Minner, Sarah; Clauditz, Till S; Jacobsen, Frank.
In: PATHOL RES PRACT, Vol. 238, 154123, 10.2022.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Diagnostic and prognostic role of pancreatic secretory granule membrane major glycoprotein 2 (GP2) immunohistochemistry: A TMA study on 27,681 tumors
AU - Uhlig, Ria
AU - Günther, Karin
AU - Bröker, Nina
AU - Gorbokon, Natalia
AU - Lennartz, Maximilian
AU - Dwertmann Rico, Sebastian
AU - Reiswich, Viktor
AU - Viehweger, Florian
AU - Büscheck, Franziska
AU - Kluth, Martina
AU - Hube-Magg, Claudia
AU - Hinsch, Andrea
AU - Fraune, Christoph
AU - Bernreuther, Christian
AU - Lebok, Patrick
AU - Sauter, Guido
AU - Izbicki, Jakob R
AU - Steurer, Stefan
AU - Burandt, Eike
AU - Marx, Andreas H
AU - Krech, Till
AU - Simon, Ronald
AU - Minner, Sarah
AU - Clauditz, Till S
AU - Jacobsen, Frank
N1 - Copyright © 2022 The Authors. Published by Elsevier GmbH.. All rights reserved.
PY - 2022/10
Y1 - 2022/10
N2 - Pancreatic secretory granule membrane major glycoprotein 2 (GP2) is a membrane component of zymogen granules which is abundantly secreted by pancreatic acinar cells. Because RNA based analyses suggest a strict limitation of GP2 expression to the pancreas in normal tissues, and a strong preference to pancreatic cancer among tumors, GP2 expression analysis might have diagnostic utility. To better understand the role of GP2 protein expression, GP2 was successfully analyzed in 27,965 tumor samples from 132 different tumor types and subtypes as well as 8 samples each of 76 different normal tissue types by immunohistochemistry in a tissue microarray format (TMA). GP2 immunostaining was seen in 14 of 16 (87.5 %) acinar cell carcinomas, 6 of 507 (1.2 %) ductal adenocarcinomas, and 3 of 99 neuroendocrine neoplasms of the pancreas (3.0 %). GP2 was also found in 23 extra-pancreatic tumor entities including several types of neuroendocrine neoplasms (14.3-58.8 %), prostatic adenocarcinomas (8.2-18.8 %), various other adenocarcinomas (0.1-7.7 %), and several categories of benign and malignant salivary gland tumors (2.3-3.1 %). A strong GP2 positivity was only seen in 6 tumor categories including 50 % of 16 pancreatic acinus cell carcinomas, 11.8 % of 17 neuroendocrine tumors of the lung, 1.3 % of 80 primary Gleason 4 + 4 % and 0.6 % of 181 recurrent prostate cancers, as well as 0.8 % of 133 adenocarcinomas of the lung. In a cohort of 14,747 prostate cancers with follow up data, GP2 immunostaining was strongly linked to advanced pT stage, high Gleason grade, lymph node metastasis, and recurrence free survival (p < 0.0001 each). The prognostic impact of GP2 positivity was independent of established parameters in TMPRSS2:ERG fusion-negative cancers (p < 0.0001). In summary, our data show that GP2 is preferentially expressed in acinar cell carcinomas of the pancreas but the glycoprotein can - rarely - also be expressed in a variety of other tumor entities.
AB - Pancreatic secretory granule membrane major glycoprotein 2 (GP2) is a membrane component of zymogen granules which is abundantly secreted by pancreatic acinar cells. Because RNA based analyses suggest a strict limitation of GP2 expression to the pancreas in normal tissues, and a strong preference to pancreatic cancer among tumors, GP2 expression analysis might have diagnostic utility. To better understand the role of GP2 protein expression, GP2 was successfully analyzed in 27,965 tumor samples from 132 different tumor types and subtypes as well as 8 samples each of 76 different normal tissue types by immunohistochemistry in a tissue microarray format (TMA). GP2 immunostaining was seen in 14 of 16 (87.5 %) acinar cell carcinomas, 6 of 507 (1.2 %) ductal adenocarcinomas, and 3 of 99 neuroendocrine neoplasms of the pancreas (3.0 %). GP2 was also found in 23 extra-pancreatic tumor entities including several types of neuroendocrine neoplasms (14.3-58.8 %), prostatic adenocarcinomas (8.2-18.8 %), various other adenocarcinomas (0.1-7.7 %), and several categories of benign and malignant salivary gland tumors (2.3-3.1 %). A strong GP2 positivity was only seen in 6 tumor categories including 50 % of 16 pancreatic acinus cell carcinomas, 11.8 % of 17 neuroendocrine tumors of the lung, 1.3 % of 80 primary Gleason 4 + 4 % and 0.6 % of 181 recurrent prostate cancers, as well as 0.8 % of 133 adenocarcinomas of the lung. In a cohort of 14,747 prostate cancers with follow up data, GP2 immunostaining was strongly linked to advanced pT stage, high Gleason grade, lymph node metastasis, and recurrence free survival (p < 0.0001 each). The prognostic impact of GP2 positivity was independent of established parameters in TMPRSS2:ERG fusion-negative cancers (p < 0.0001). In summary, our data show that GP2 is preferentially expressed in acinar cell carcinomas of the pancreas but the glycoprotein can - rarely - also be expressed in a variety of other tumor entities.
U2 - 10.1016/j.prp.2022.154123
DO - 10.1016/j.prp.2022.154123
M3 - SCORING: Journal article
C2 - 36137400
VL - 238
JO - PATHOL RES PRACT
JF - PATHOL RES PRACT
SN - 0344-0338
M1 - 154123
ER -
